Key Takeaways
- Truist Securities elevates Biogen rating to Buy from Hold, increasing price target from $190 to $235
- Rating change precedes July 14 Phase 2 data disclosure for Alzheimer’s treatment diranersen
- Shares gained 1.3% in early Monday trading, reaching $201.63
- Analyst firm incorporates probability-adjusted revenue projections for lupus therapies litifilimab and felzartamab
- Upcoming Q2 financial results scheduled for July 29 not viewed as significant market mover by Truist
Truist Securities revised its stance on Biogen (BIIB) Monday morning, elevating the biotechnology company to Buy from Hold while simultaneously increasing the price target to $235 from $190. Based on Friday’s close of $199.15, this represents potential upside of approximately 18%.
Shares advanced 1.3% to $201.63 during premarket hours. Despite declining 7.8% throughout the current month, the stock maintains a 13% year-to-date gain, outperforming the S&P 500’s 11% advance.
The timing of this upgrade coincides with Biogen’s scheduled appearance Tuesday at the Alzheimer’s Association International Conference taking place in London. During this event, the pharmaceutical company will reveal comprehensive Phase 2 results for diranersen, its investigational Alzheimer’s treatment.
This past May, Biogen disclosed that diranersen failed to achieve its primary endpoint in Phase 2 testing. Nevertheless, management indicated intentions to proceed with Phase 3 development, and Tuesday’s detailed presentation should provide clarity regarding this strategic decision.
Truist characterized its outlook on the stock as “increasingly constructive,” citing expectations that the diranersen data release could function as a substantial positive catalyst. The investment firm identifies “attractive risk/reward” dynamics leading into what it describes as “de-risking pivotal data readouts.”
Expanding Pipeline Opportunities
Truist’s positive perspective extends beyond the Alzheimer’s program. The firm highlighted multiple late-stage pipeline milestones anticipated within the coming two years as important value drivers.
This encompasses a Phase 3 data release for litifilimab, a lupus treatment, expected in Q4 2026, along with felzartamab results in antibody-mediated rejection projected for mid-2027.
Truist assigned 50% risk-adjusted peak revenue estimates of approximately $750 million for litifilimab and 65% probability-weighted sales of about $500 million for felzartamab in antibody-mediated rejection, accompanied by $260 million in primary membranous nephropathy.
These pipeline additions increased Truist’s 2035 revenue projection by roughly $1.5 billion, providing justification for the elevated price target.
The firm contends that market valuations haven’t fully reflected the commercial opportunity embedded in Biogen’s Alzheimer’s disease and immunology development programs.
Partner Performance Matters
Those following Biogen should also monitor Ionis Pharmaceuticals, a collaborative development partner. Ionis shares tumbled last week following an unexpected clinical failure of a cardiovascular drug developed alongside AstraZeneca.
Truist indicated it doesn’t consider Biogen’s Q2 financial report, scheduled for July 29, as a primary catalyst.
Rather, the firm anticipates pipeline developments—beginning with Tuesday’s diranersen presentation—will shape investor sentiment throughout upcoming quarters.
Biogen stock has delivered a 13% return through 2026 to date.
